Research news A University of Texas at El Paso study has found that people with type 2 diabetes or obesity who used glucagon-like peptide-1 receptor agonists had lower odds of alcohol, opioid, nicotine and cocaine use disorders, although researchers said clinical trials were needed before the drugs could be considered for addiction treatment A study led by researchers at The University of Texas at El Paso, USA, has found that the use of diabetes and weight loss medicines such as Ozempic was associated with a lower risk of alcohol, opioid, nicotine and cocaine use disorders
Contemporary issues surrounding folic acid fortification initiatives
Dose Escalation GLP-1 medications are typically introduced at a low dose and increased gradually
What changes is the speed of weight loss, not the way the medicine works
However, it is possible that cells weakly expressing GLP-1R may generate insufficient Cre recombinase to activate the fluorescent reporters
July 2024: A study published in JAMA Ophthalmology suggests that Ozempic users could be at higher risk of NAION, a condition that can cause sudden and permanent vision loss